Physician profile
Catherine M Rezendes
NPI 1720002579
$33,121.40
in general payments reported to CMS, 2019-2025
22 companies · $26K in 2025
The $26K reported for 2025 was more than what 99% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $183 · 2021: $315 · 2022: $1,935 · 2023: $1,346 · 2024: $2,970 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $25K · Food and Beverage: $3,551 · Travel and Lodging: $1,812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $25,200.00 |
| Food and Beverage | $3,550.79 |
| Travel and Lodging | $1,812.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $28,547.76 | 2023-2025 | |
| Triad Life Sciences INC. | $1,632.41 | 2022 | |
| Paratek Pharmaceuticals, INC. | $899.49 | 2021-2025 | Nuzyra |
| Kerecis Limited | $623.33 | 2019-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Organogenesis INC. | $418.88 | 2020-2025 | Affinity, Puraply, Via Matrix |
| Nevro Corp. | $174.65 | 2022-2023 | Senza |
| Smith+Nephew, INC. | $168.58 | 2020-2025 | Collagenase Santyl, Regranex, Renasys Touch |
| Ibsa Pharma INC. | $119.87 | 2023-2024 | Licart, Tirosint |
| Stryker Corporation | $109.94 | 2025 | Hydroset, Augment Injectable |
| Averitas Pharma INC. | $95.27 | 2023-2025 | Qutenza |
| Fusion Orthopedics USA, LLC | $63.94 | 2024 | |
| Sebela Pharmaceuticals INC. | $63.81 | 2019 | |
| Medtronic, INC. | $38.22 | 2022 | |
| Treace Medical Concepts, INC. | $33.31 | 2023 | |
| Arthrosurface Incorporated | $26.90 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $20.63 | 2023 | Krystexxa |
| Abbott Laboratories | $18.30 | 2023 | Proclaim |
| Medline Industries Lp | $16.71 | 2022 | |
| Biocomposites INC | $15.32 | 2023 | Stimulan |
| Kci USA, INC. | $13.29 | 2019 | |
| Hartmann USA, INC. | $11.77 | 2021 | |
| Orthofix Medical, INC. | $9.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Rezendes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.